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Controlling maleimide hydrolysis allows the modular construction
of bromomaleimide-mediated bioconjugates which are either
stable or cleavable in an aqueous, thiol-mediated reducing
environment. The application of this methodology to reversible
protein biotinylation, the irreversible labeling of peptide disulﬁde
bonds and the assembly of stable, ﬂuorescein-labelled glycoprotein
mimics is described.
The advent of chemical biology has demonstrated the power
of integrating synthetic chemistry methods with molecular
biology to derive functionally interesting proteins either as
probes or therapeutics. Chemical modiﬁcation of proteins has
allowed the synthesis of a variety of probes via introduction of
synthetic post-translational modiﬁcations1–3 and a variety of
ﬂuorescent,4–6 radiolabelled7 and aﬃnity tags.8–10 The selective
chemical modiﬁcation of the sulfhydryl group of cysteine
has proved a facile method to achieve protein modiﬁcation.
This is due to the rare occurrence of free cysteine in protein
sequences, the fact that it is the most nucleophilic of all amino
acid side chain residues and that in principle modern molecular
biology methods allow the introduction of a free cysteine
anywhere in a protein.11,12
We recently described an approach to reversible cysteine
bioconjugation using bromomaleimides, that allows the modular
construction of complex bioconjugates in very high yields with
no requirement for prior activation of reactants.13 However,
although reversible labeling of peptides and proteins is of
considerable value, there are many circumstances under which
a permanent, irreversible modiﬁcation is required. We now
wish to report the development of maleimides that maintain
three points of chemical attachment but whose stability can be
controlled by a simple hydrolysis protocol so that they can
be either cleavable or stable in the presence of an aqueous,
thiol-mediated reducing environment. Such control of stability
allows the synthesis of a range of complex bioconjugates with
signiﬁcantly diﬀerent potential. In principle, stable conjugation
allows the construction of non-cleavable PTM mimics suitable
for evaluation as probes or therapeutics. Cleavable conjugates
could be used to generate reversible aﬃnity and ﬂuorescent
labels, or constructs cleavable under cytoplasmic conditions
with potential as prodrugs.
We noted that though maleimides react in a facile manner
with thiol nucleophiles, maleamic acids do not (see ESIw). We
therefore considered that it should be possible to convert a
reversible maleimide-based bioconjugation to an irreversible
bioconjugation by careful choice of reagent and through
careful hydrolysis of the original bioconjugate. The realisation
of this concept was demonstrated by use of N-phenyl-bromo-
maleimides 2 and 5. The susceptibility of N-arylmaleimides to
hydrolysis has been previously reported in the literature.14
We exempliﬁed our approach using a single point mutant
(L111C) of the SH2 domain of the Grb2 adapter protein 1.13a
Thus treatment of protein 1 with a stoichiometric equivalent
of N-phenylbromomaleimide 2 at pH 8, 0 1C for 1 h yielded 3.
Conjugate 3 was stable at 0 1C but on heating to 37 1C for 4 h,
quantitative hydrolysis of the maleimide was observed to give
4, presumably as a mixture of regioisomers, which was com-
pletely stable to 2-mercaptoethanol (BME) and glutathione
(GSH) (0 1C, 20 1C, 37 1C) (Scheme 1).
Scheme 1 From reversible to irreversible protein modiﬁcation with
N-phenylbromomaleimide.
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Hydrolysis of conjugates of protein 1 with N-phenyl-
dibromomaleimide 5 was even more facile. Treatment of
protein 1 with one equivalent of 5 at pH 8 gave a 7 : 3 mixture
of maleimide 6 and hydrolysed product 7 even at 0 1C.
However, performing the same procedure at pH 6 allowed
clean conversion of protein 1 to 6, and then treatment of 6
with one equivalent of thioglucose, sodium salt 8 furnished
bioconjugate 9. Bioconjugate 9 was shown to be hydrolytically
stable at pH 6, 0 1C for44 h. Treatment of 9 with excess BME
at 0 1C gave complete cleavage to protein 1. Exchanging the
buﬀer environment of a solution of bioconjugate 9 from pH 6
to 8 yielded bioconjugate 10 which was stable to BME and
GSH (0 1C, 20 1C, 37 1C), highlighting that maleimide hydrolysis
could be utilized to stabilize an assembled bioconjugate to
thiol-mediated cleavage (Scheme 2).
With methods in hand to generate both cleavable and stable
maleimide-bridged bioconjugates we sought to demonstrate
the strength and versatility of this methodology with some
speciﬁc examples.
Use of the biotin–avidin interaction, to facilitate biotin-
labelled protein enrichment or immobilisation, is a well
established technique.15 The method is, however, limited by
the fact that breaking of this interaction, to ultimately retrieve
the protein sample, requires very harsh, denaturing conditions
which are not experimentally useful, e.g. boiling buﬀer
containing sodium dodecyl sulfate (SDS) or 8 M guanidine
(pH 1.5). Two strategies have been developed to address this
problem. The ﬁrst approach requires design of analogues of
biotin which bind with lower aﬃnity to avidin.16 Though very
useful, this approach is hampered as increased ease of elution
comes at the price of weaker initial binding. A second
approach is to design aﬃnity probes which maintain the native
biotin–avidin interaction but which incorporate a cleavable
linker.8,9 Given the robust hydrolytic stability of N-methyl-
bromomaleimide-modiﬁed 1 (stable for 4 h, pH 8, 37 1C, see
ESIw), we were encouraged to design and synthesise cleavable
aﬃnity tag 11 (Fig. S1, see ESIw). We envisaged that this tag
would allow facile pull-down of proteins onto an avidin-
modiﬁed surface whilst supporting mild cleavage conditions
in mM concentrations of BME. BME is widely used in
molecular biology and is known to be compatible with proteins.
A further potential advantage of tag 11 is that native protein
would be released upon cleavage.
To demonstrate the utility of 11, we attempted the deriva-
tisation, pull-down and release of protein 1. Treatment of 1
with a stoichiometric equivalent of 11 at pH 8, 0 1C gave
quantitative conversion to the desired biotinylated conjugate
12 after 1 h. Conjugate 12 was demonstrably stable in the
absence of thiol (37 1C, pH 8, 1 h). The protein solution was
then applied to neutravidin-coated agarose beads to facilitate
protein pull-down. Release of 1 from the beads was successfully
achieved on suspension in PBS buﬀer containing 25 mM BME
for 2 h at 37 1C (Scheme 3).
We believe that BME initially reacts with 12 to generate the
saturated bisthio adduct.13a At elevated temperatures, this
adduct can undergo a reversible retro-Michael reaction which
allows liberation of the protein in an excess of the thiol. 77% of
immobilized protein was recovered following this pull-down/
release protocol (see ESIw for gels and detailed experimental).
Fluorescent labeling of proteins is a powerful technique for
studying localization, protein dynamics and protein–protein
interactions.17 Within the ﬁeld of medical imaging, optical
imaging is becoming more widely used as a technique as it has
a sensitivity of the same order as radionuclide imaging, with
far greater spatial and temporal resolution, and no requirement
for radioactive materials. We have previously reported that
dibromomaleimide reagents can be used successfully to reversibly
modify the disulﬁde bond of peptide hormone somatostatin.13a
To exemplify this discovery, we demonstrated the reversible
insertion of a ﬂuorescent probe into the disulﬁde bond. We
now wish to demonstrate how when using an N-arylmaleimide
derived ﬂuorophore this process can be made irreversible
ensuring the potential for continued attachment of the
Scheme 2 Irreversible protein bioconjugation using N-phenyl-dibromo-
maleimide.
Scheme 3 Cleavable biotinylation of protein 1 with aﬃnity tag 11.
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ﬂuorophore in a biological environment. Somatostatin was
modiﬁed with N-ﬂuoresceindibromomaleimide (pH 6.2) to
yield cleavable conjugate 13 as previously described.13a Heating
the solution of 13 (pH 8) to 37 1C for 24 h facilitated complete
maleimide hydrolysis yielding non-cleavable conjugate 14
(Scheme 4).
A similar strategy can also be employed to generate
non-cleavable, ﬂuorescent bioconjugates via the modiﬁcation
of a single cysteine residue. Applying the bioconjugate assembly
strategy outlined in Scheme 2 to protein 1, but using
N-ﬂuoresceindibromomaleimide in place of 5, gave access to
non-cleavable, ﬂuorescently-labelled glycoprotein mimic 15
(Scheme 5).
In conclusion, we have demonstrated the use of bromo-
maleimides for the generation of complex bioconjugates,
maintaining three points of attachment, which are either
cleavable or non-cleavable in the presence of an excess of thiol
such as BME or GSH. The switch from reversible modiﬁcation
to an irreversible linkage was achieved by controlled
maleimide hydrolysis post-conjugate assembly. N-alkylated
mono- or bisthio-maleimides appear quite stable to hydrolysis,
even at pH 8 and physiological temperature, yielding conjugates
which are cleavable in an excess of thiol. N-arylated mono- or
bisthio-maleimides can be assembled in a facile manner at pH 6
but hydrolyse rapidly at pH 8 yielding conjugates which are
non-cleavable. We have demonstrated that thiol-mediated
cleavage can be applied to the design and application of a
novel aﬃnity tag which allows the successful pull-down of a
cysteine containing protein onto neutravidin beads. Cleavage,
under mild conditions, releases the native protein in good
yield. We have also demonstrated the synthesis of both
ﬂuorescently-labelled and unlabelled, thiol-stable glycoprotein
mimics and thiol-stable ﬂuorescent labeling of a disulﬁde
bond. We envisage numerous potential applications for these
technologies including PTM of proteins; aﬃnity tagging and
protein labelling; PEGylation; prodrugs designed to cleave in
cells. Further applications and developments using this versatile
methodology will be reported in due course. The authors are
grateful to RCUK, EPSRC, BBSRC, the Wellcome Trust and
UCLB for support of our programme.
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Scheme 4 Reversible and irreversibleﬂuorescent labellingof somatostatin.
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